Infos zu Corona - Aktuelle Informationen zu SARS-CoV-2 : 14b monoklonale Antikörper

14b monoklonale Antikörper » Regkirona (Regdanvimab) Celltrion

Letzte Änderung: 19.11.2022 um 18:57 Uhr

Regdanvimab bzw. CT-P59 scheint leider nicht mehr gegen Omicron wirksam zu sein. Es hat keine Wirksamkeit gegen BA.1, BA.4/5, BA.4.6, BJ.1 oder z.B. BQ.1.1. Gegen BA.2.75.2 hat es noch eine minimalste Restwirksamkeit.

Weiterführende Links zum Artikel

★ Omicron sublineage BQ.1.1 resistance to monoclonal antibodies (Hinzugefügt: 19.11.2022 um 18:57 Uhr)
https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(22)00733-2/fulltext
★ COVID-19: EMA recommends authorisation of two monoclonal antibody medicines (Hinzugefügt: 21.11.2021 um 08:14 Uhr)
https://www.ema.europa.eu/en/news/covid-19-ema-recommends-authorisation-two-monoclonal-antibody-medicines
★ CONDITIONS OF USE, CONDITIONS FOR DISTRIBUTION AND PATIENTS TARGETED AND CONDITIONS FOR SAFETY MONITORING (Hinzugefügt: 29.03.2021 um 06:15 Uhr)
https://www.ema.europa.eu/en/documents/referral/celltrion-use-regdanvimab-treatment-covid-19-article-53-procedure-conditions-use-conditions_en.pdf
Reported in vitro Therapeutic Activity (Hinzugefügt: 18.12.2021 um 15:22 Uhr)
https://opendata.ncats.nih.gov/variant/activity
EMA GIBT ZULASSUNG FÜR ANTIKÖRPERTHERAPIEN GEGEN COVID-10 (Hinzugefügt: 18.12.2021 um 14:01 Uhr)
https://www.mdr.de/brisant/neue-corona-medikamente-100.html
COVID-19: Zwei Antikörperpräparate in Europa vor der Zulassung (Hinzugefügt: 18.12.2021 um 14:01 Uhr)
https://www.aerzteblatt.de/nachrichten/129034/COVID-19-Zwei-Antikoerperpraeparate-in-Europa-vor-der-Zulassung
EMA receives application for marketing authorisation for Regkirona (regdanvimab) for treating patients with COVID-19 Share (Hinzugefügt: 18.12.2021 um 14:01 Uhr)
https://www.ema.europa.eu/en/news/ema-receives-application-marketing-authorisation-regkirona-regdanvimab-treating-patients-covid-19
Considerable escape of SARS-CoV-2 variant Omicron to antibody neutralization (Hinzugefügt: 17.12.2021 um 10:25 Uhr)
https://www.biorxiv.org/content/10.1101/2021.12.14.472630v1.full.pdf
Celltrion says trial shows antibody COVID-19 treatment to be safe and effective (Hinzugefügt: 20.06.2021 um 17:59 Uhr)
https://www.reuters.com/business/healthcare-pharmaceuticals/celltrion-says-trial-shows-antibody-covid-19-treatment-be-safe-effective-2021-06-14/
Celltrion's COVID-19 antibody gets a phase 3 win as virus variants snare existing therapies (Hinzugefügt: 14.06.2021 um 16:26 Uhr)
https://www.fiercebiotech.com/biotech/celltrion-s-covid-19-antibody-cuts-hospitalizations-deaths-phase-3
Celltrion announces positive top-line results from global Phase III trial of regdanvimab (CT-P59), an anti-COVID-19 monoclonal antibody treatment (Hinzugefügt: 14.06.2021 um 16:26 Uhr)
https://www.businesswire.com/news/home/20210614005275/en/Celltrion-announces-positive-top-line-results-from-global-Phase-III-trial-of-regdanvimab-CT-P59-an-anti-COVID-19-monoclonal-antibody-treatment
Celltrion confirms neutralizing potency against emerging SARS-CoV-2 variants of treatment with the anti-COVID-19 monoclonal antibody regdanvimab (CT-P59) (Hinzugefügt: 22.05.2021 um 17:55 Uhr)
https://www.explica.co/celltrion-confirms-neutralizing-potency-against-emerging-sars-cov-2-variants-of-treatment-with-the-anti-covid-19-monoclonal-antibody-regdanvimab-ct-p59.html
Celltrion Confirms Neutralising Potency Against Emerging SARS-CoV-2 Variants With Anti-COVID-19 Monoclonal Antibody Treatment regdanvimab (CT-P59) (Hinzugefügt: 20.05.2021 um 06:25 Uhr)
https://www.pharmiweb.com/press-release/2021-05-19/celltrion-confirms-neutralising-potency-against-emerging-sars-cov-2-variants-with-anti-covid-19-monoclonal-antibody-treatment-regdanvimab-ct-p59
Global sale of Celltrion's COVID-19 antibody-drug Regkirona begins (Hinzugefügt: 13.05.2021 um 17:30 Uhr)
https://www.indiatvnews.com/news/world/celltrion-covid19-antibody-drug-regkirona-begins-704041
Celltrion’s anti-COVID 19 monoclonal antibody treatment, regdanvimab (CT-P59), demonstrates neutralising effect against the South African variant (B.1.351) (Hinzugefügt: 02.05.2021 um 03:13 Uhr)
https://www.pharmiweb.com/press-release/2021-04-30/celltrion-s-anti-covid-19-monoclonal-antibody-treatment-regdanvimab-ct-p59-demonstrates-neutralising-effect-against-the-south-african-variant-b1
EMA recommends use of Celltrion’s regdanvimab for Covid-19 treatment (Hinzugefügt: 30.03.2021 um 08:27 Uhr)
https://www.pharmaceutical-technology.com/news/ema-recommends-celltrion-regdanvimab/
EMA issues advice on use of regdanvimab for treating COVID-19 (Hinzugefügt: 29.03.2021 um 06:15 Uhr)
https://www.ema.europa.eu/en/news/ema-issues-advice-use-regdanvimab-treating-covid-19
EMA issues advice on use of regdanvimab for treating COVID-19 (Hinzugefügt: 26.03.2021 um 20:44 Uhr)
https://www.ema.europa.eu/en/news/ema-issues-advice-use-regdanvimab-treating-covid-19
EMA sets 12 March J&J vaccine meeting; Celltrion's mAb gets Article 5(3) review (Hinzugefügt: 03.03.2021 um 08:09 Uhr)
https://www.raps.org/news-and-articles/news-articles/2021/3/ema-sets-12-march-jj-vaccine-meeting-celltrions-ma

14b monoklonale Antikörper » Regkirona (Regdanvimab) Celltrion

Mehr zum Thema "14b monoklonale Antikörper"

Weitere Themen